LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Search

Ligand Pharmaceuticals Inc

Închisă

SectorSănătate

189.61 3.86

Rezumat

Modificarea prețului

24h

Curent

Minim

186.18

Maxim

190.21

Indicatori cheie

By Trading Economics

Venit

112M

117M

Vânzări

115M

P/E

Medie Sector

81.352

77.671

Marjă de profit

101.569

Angajați

68

EBITDA

87M

149M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+28.46% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-485M

3.6B

Deschiderea anterioară

185.75

Închiderea anterioară

189.61

Sentimentul știrilor

By Acuity

80%

20%

350 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 dec. 2025, 22:53 UTC

Achiziții, Fuziuni, Preluări

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13 dec. 2025, 00:04 UTC

Achiziții, Fuziuni, Preluări

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14 dec. 2025, 23:46 UTC

Market Talk

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14 dec. 2025, 23:36 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14 dec. 2025, 22:38 UTC

Achiziții, Fuziuni, Preluări

Fortescue to Take Full Control of US$101M Copper Miner Alta

14 dec. 2025, 22:02 UTC

Achiziții, Fuziuni, Preluări

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14 dec. 2025, 22:01 UTC

Achiziții, Fuziuni, Preluări

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14 dec. 2025, 22:01 UTC

Achiziții, Fuziuni, Preluări

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14 dec. 2025, 22:00 UTC

Achiziții, Fuziuni, Preluări

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14 dec. 2025, 22:00 UTC

Achiziții, Fuziuni, Preluări

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14 dec. 2025, 21:59 UTC

Achiziții, Fuziuni, Preluări

Fortescue to Acquire Remaining 64% of Alta Copper

14 dec. 2025, 17:00 UTC

Câștiguri

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14 dec. 2025, 08:30 UTC

Achiziții, Fuziuni, Preluări

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13 dec. 2025, 16:48 UTC

Achiziții, Fuziuni, Preluări

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dec. 2025, 08:00 UTC

Achiziții, Fuziuni, Preluări

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dec. 2025, 07:00 UTC

Achiziții, Fuziuni, Preluări

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 dec. 2025, 00:24 UTC

Achiziții, Fuziuni, Preluări

Want a Piece Of SpaceX? -- Barrons.com

12 dec. 2025, 23:49 UTC

Achiziții, Fuziuni, Preluări

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dec. 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dec. 2025, 22:32 UTC

Câștiguri

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 dec. 2025, 20:45 UTC

Câștiguri

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dec. 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dec. 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dec. 2025, 19:23 UTC

Câștiguri

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dec. 2025, 18:35 UTC

Achiziții, Fuziuni, Preluări

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dec. 2025, 18:33 UTC

Achiziții, Fuziuni, Preluări

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dec. 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dec. 2025, 17:49 UTC

Câștiguri

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dec. 2025, 17:34 UTC

Achiziții, Fuziuni, Preluări

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Comparație

Modificare preț

Ligand Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

28.46% sus

Prognoză pe 12 luni

Medie 243.5 USD  28.46%

Maxim 275 USD

Minim 220 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLigand Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

7

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

102.5 / 109.24Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Very Strong Bearish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

350 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat